Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene’s Otezla Shines, On Track To Be A Fourth Blockbuster Pillar

Executive Summary

Sales of the psoriasis drug increased 170% in the second quarter to $242m, giving the blood cancer specialist a strong anchor as it looks to expand in inflammation and immunology.


Related Content

VC Roundup: Cleave Raises $37m To Maintain Phase I Momentum, Plus $233.5m In Recent Financings
Celgene’s Otezla Gets Preliminary Nod From NICE At Second Attempt
Blow For Celgene As Revlimid Trial Miss Removes Blockbuster Indication
Roche Builds Hematology Pipeline Beyond B-Cell Disease
Clarity For Celgene On Revlimid, A Backbone Of MM Treatment
Multiple Myeloma Market Snapshot: New Drugs And Big Changes
Celgene Sets Sights On Becoming Inflammation and Immunology Power Player
Celgene Makes A Play For Inflammation & Immunology Stake With Apremilast


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts